Launching a First Precision Medicine at a Small Biotech With Limited Infrastructure
A plan for a small biotech launching its first precision medicine: diagnostic strategy, what to outsource, a minimum viable data stack, and budget phasing.
The short answer
A small biotech launching its first precision medicine should spend its limited resources on the testing step first: map which HCPs and accounts test for the biomarker, educate where testing falls short, and align with the diagnostic partner on access and turnaround. Keep strategy, the target list, and MLR ownership in-house; outsource media buying, data onboarding, and measurement. Start with a minimum viable data stack keyed on NPI and phase budget so most paid media lands after approval, with a holdout built in from the start.
A big pharma precision oncology launch has a diagnostics team, an analytics group, a field force sized by the hundreds, and an agency roster. A small biotech launching its first product might have a commercial lead, a marketing director, a medical affairs head, and a budget that has to cover everything. The good news is that a narrow, biomarker-defined population rewards focus. The bad news is that there is no slack for mistakes in sequencing.
This article is part of the series on diagnostic data in precision medicine launches. It is general planning guidance, not regulatory or legal advice.
A prioritized plan for a small biotech launch
- Lock the diagnostic path. Know which test or tests identify your patients, whether there is a companion diagnostic, which labs offer it, typical turnaround, and how it is reimbursed. Work with the diagnostic partner on lab availability before you worry about media.
- Map testing. License or commission HCP-level testing data for your marker. Find the HCPs and accounts that test, and the high-opportunity ones that do not.
- Build one target list. NPI-keyed, two axes (category opportunity and testing behavior), owned by one person. See integrating diagnostic data into HCP targeting.
- Plan unbranded testing education. Through medical affairs and disease education, reviewed through MLR, aimed at the testing gap.
- Size the field. Use the testing map to decide where people are needed. Testing gaps at large accounts usually need humans.
- Set up measurement before launch. Define a holdout and a pre-period now.
- Launch branded media to high-testing prescribers. Then expand as testing grows.
What to outsource and what to keep
| Function | Keep in-house | Outsource |
|---|---|---|
| Brand strategy and positioning | Yes | Agency support for execution |
| Target list definition | Yes, one owner | Data vendor builds the inputs |
| MLR process | Yes, own the process and approvals | Agency prepares submissions |
| Media planning and buying | Set goals and approve plans | Agency or specialist buyer |
| HCP data and onboarding | Vendor selection, privacy sign-off | Data and identity partners |
| Measurement | Define questions and holdouts | Measurement partner runs analysis |
| Field force | Leadership and targeting | Contract sales organization if needed |
| Diagnostic partnership | Relationship and strategy | Lab services through the partner |
The rule I would use: keep anything where a wrong call changes who you target or what you claim. Outsource execution. In-house, agency, or hybrid programmatic covers the media side of that decision in more depth.
The minimum viable data stack
Small teams overbuy data because every vendor shows a compelling slide. Start with what drives a decision:
- Testing data at the HCP level for your marker. This is the one source you probably cannot skip.
- Prescribing data for the category now, and for your brand once it is on market.
- An NPI-keyed master list in a simple warehouse. Early on, a well-governed spreadsheet with version control can work for a list of a few thousand.
- A CRM for the field with the same tiers.
- One onboarding or HCP platform partner for media activation.
Before signing anything, check how to judge diagnostic data accuracy and hidden costs in HCP data contracts. Minimum commitments sized for large brands hit small biotechs hardest.
Budget phasing with limited funds
An illustrative split across the 18 months around approval, using hypothetical percentages of a total commercial media and data budget:
| Phase | Timing | Illustrative share | Main spend |
|---|---|---|---|
| Map | 12 to 6 months before approval | 10% | Testing data, list build, measurement setup |
| Educate | 6 months before to approval | 20% | Unbranded testing education, pathology and lab outreach |
| Launch | Approval to month 6 | 45% | Branded HCP media, field support, first measurement read |
| Adjust | Months 6 to 12 | 25% | Reallocation based on testing uplift and early starts |
The shares add to 100 percent. Keep some of the launch phase uncommitted so you can move money after the first read. How much budget to reserve for learning and the drug launch media plan help size the rest.
Mistakes small teams make most often
- Spending branded media before testing is in place at key accounts.
- Licensing three overlapping data sources, then using none fully.
- No holdout, so the first board update has no defensible result.
- Letting the agency own the target list.
- Forgetting transparency reporting obligations for HCP payments, such as Open Payments, when planning speaker programs or advisory boards.
Practical takeaway
Write a one-page launch brief this month that names the test, the labs that run it, the turnaround, the top 50 accounts by testing opportunity, and the single owner of the target list. If any of those lines is blank, that is your next task, ahead of agency selection or media planning.
Frequently asked questions
What should a small biotech do first for a precision medicine launch?
Map testing. Before building media or a large field team, find out which HCPs and accounts test for your biomarker, with what test types, and where results come back. That map sets the target list, the education priorities, and the field footprint.
What should a small biotech outsource at launch?
Commonly outsourced functions include media buying, HCP data and onboarding, measurement, and sometimes a contract field force or medical science liaison support. Keep brand strategy, the target list definition, MLR ownership, and vendor management in-house, because those decisions cannot be delegated without losing control of the launch.
What is a minimum viable data stack for a precision medicine launch?
One source of HCP-level testing data, one source for prescribing data once the brand is on market, an NPI-keyed master list in a simple warehouse or even a well-governed spreadsheet, a CRM for the field, and an onboarding partner for media. Add more only when a specific decision needs it.
Sources
- U.S. Food and Drug Administration, Companion Diagnostics
- National Cancer Institute, Biomarker Testing for Cancer Treatment
- U.S. Food and Drug Administration, Office of Prescription Drug Promotion (OPDP)
- CMS, Open Payments
External guidance and platform documentation change. Links were current at publication; check them again before relying on them for a decision.
Editorial note. Analysis and frameworks are the author's own and do not represent Acxiom or any current or former employer, client, or named platform. Examples labeled hypothetical or illustrative are not results from real campaigns. Nothing here is legal, regulatory, or medical advice.
New pharma programmatic breakdowns, occasionally
One email when I publish something worth reading. Benchmarks, measurement teardowns, and case studies with the caveats attached. No cadence promises, no reselling your address.
Unsubscribe any time. See the privacy policy.
Working through this decision on a real plan?
I work on health and pharma data, identity, and activation, after five years running HCP and DTC programmatic agency-side. Happy to talk through how this applies to your situation.